Edition:
United States

Eckert & Ziegler BEBIG SA (EZBG.BR)

EZBG.BR on Brussels Stock Exchange

8.65EUR
10:00am EDT
Change (% chg)

€-0.05 (-0.57%)
Prev Close
€8.70
Open
€8.65
Day's High
€8.65
Day's Low
€8.65
Volume
96
Avg. Vol
400
52-wk High
€11.50
52-wk Low
€6.20

Chart for

About

Eckert & Ziegler BEBIG SA is a Belgium-based company involved in the active implantable medical devices segment of the health care sector. The Company designs, develops and distributes interstitial implants used in brachytherapy for the treatment of cancer. The Company produces and markets three lines of products: Permanent... (more)
No analyst recommendations are available for .

Overall

Beta: 0.82
Market Cap(Mil.): €20.27
Shares Outstanding(Mil.): 2.33
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 29.78 16.18
EPS (TTM): -- -- --
ROI: -- 6.59 14.60
ROE: -- 10.42 13.87

BRIEF-Eckert & Ziegler BEBIG H1 operating results rises to 1.9 million euros

* H1 NET PROFIT EUR 1.4 MILLION VERSUS LOSS OF EUR 172,000 YEAR AGO

Aug 02 2017

BRIEF-Eckert & Ziegler H1 total sales up at EUR 64.8 mln

* NEARLY DOUBLED ITS PROFIT PER SHARE BY 0.91 EUR TO 1.83 EUR IN FIRST HALF YEAR

Aug 02 2017

BRIEF-Eckert & Ziegler increases profit forecast for FY 2017

* ECKERT & ZIEGLER INCREASES PROFIT FORECAST FOR FINANCIAL YEAR 2017

Jul 25 2017

BRIEF-Eckert & Ziegler Q1 sales up by 5% yoy to EUR 37.6 mln

* ECKERT & ZIEGLER: SALES GROWTH AND JUMP IN INCOME IN FIRST QUARTER

May 09 2017

BRIEF-Eckert & Ziegler signs agreement to sell its cyclotron division

* Signs agreement to sell its cyclotron division to Alliance Medical

May 05 2017

BRIEF-Eckert & Ziegler BEBIG FY EBITDA swings to profit of 2.7 million euros

* FY ebitda 2.7 million euros ($2.92 million) versus loss of 228,000 euros year ago

Mar 23 2017

BRIEF-Eckert & Ziegler posts FY sales of 138.0 million euros

* 2016 annual financial statements: sales and profit according to plan. Gross profit margin up by 6 pct. Change in the supervisory board.

Mar 23 2017

BRIEF-Eckert & Ziegler BEBIG announces end of shortage of iodine isotopes

* Announces that the shortage of iodine isotopes for production of its brachytherapy implantation seeds has been overcome Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Mar 20 2017

Earnings vs. Estimates

No consensus analysis data available.